Reset filter
Keywords
AML ×
Mostra di più Keywords
Sommario
  1. 1. Klinische studie
  2. 2. Routinedocumentatie
  3. 3. Register-/kohortstudies
  4. 4. Kwaliteitswaarborging
  5. 5. Datastandaard
  6. 6. Patiëntenvragenlijst
  7. 7. Medisch vakgebied
    1. 7.1. Anesthesie
    1. 7.2. Dermatologie
    1. 7.3. HNO
    1. 7.4. Geriatrie
    1. 7.5. Gynaecologie/Ostetrie
    1. 7.6. Interne geneeskunde
      1. Hematologie
      1. Epidemiologie
      1. Cardiologie/Angiologie
      1. Pneumologie
      1. Gastro-enterologie
      1. Nefrologie
      1. Endocrinologie/Metabolisme
      1. Rheumatologie
    1. 7.7. Neurologie
    1. 7.8. Oogheelkunde
    1. 7.9. Palliatieve zorg
    1. 7.10. Pathologie/Forensische Geneeskunde
    1. 7.11. Kindergeneeskunde
    1. 7.12. Psychiatrie/Psychosomatisch
    1. 7.13. Radiologie
    1. 7.14. Chirurgie
      1. Algemene/maag-darm-chirurgie
      1. Neurochirurgie
      1. Plastische chirurgie
      1. Cardiothoracale chirurgie
      1. Traumachirurgie/Orthopedie
      1. Vaatchirurgie
    1. 7.15. Urologie
    1. 7.16. Tandheelkunde/MKG
Modelli di dati selezionati

Devi effettuare il log in per selezionare i modelli di dati da scaricare per successive analisi

242 Risultati di ricerca.
rilevanza Valutazione Più recente Meno recente

Eligibility Leukemia NCT00469820

- 03-08-17 - 1 modulo, 1 ItemGroup, 15 elementi, 1 linguaggio
ItemGroup: Criteria
Vaccine Therapy With or Without Donor Lymphocyte Infusion in Treating Patients With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Multiple Myeloma Undergoing Donor Stem Cell Transplant; ODM derived from: https://clinicaltrials.gov/show/NCT00469820

Eligibility Leukemia NCT00899171

- 19-05-18 - 1 modulo, 1 ItemGroup, 10 elementi, 1 linguaggio
ItemGroup: Criteria
S9031-S9126-S9333-S9500-A, Studying Bone Marrow and Blood Samples From Patients With Acute Myeloid Leukemia; ODM derived from: https://clinicaltrials.gov/show/NCT00899171

Eligibility Leukemia NCT00887068

- 18-05-18 - 1 modulo, 2 itemgroups, 16 elementi, 1 linguaggio
Itemgroups: Inclusion Criteria, Exclusion Criteria
Randomized Allogeneic Azacitidine Study; ODM derived from: https://clinicaltrials.gov/show/NCT00887068

Eligibility Leukemia NCT00775593

- 17-05-18 - 1 modulo, 1 ItemGroup, 23 elementi, 1 linguaggio
ItemGroup: Criteria
Clofarabine and Temsirolimus in Treating Older Patients With Relapsed or Refractory Acute Myeloid Leukemia; ODM derived from: https://clinicaltrials.gov/show/NCT00775593

Eligibility Leukemia NCT00554489

- 16-05-18 - 1 modulo, 1 ItemGroup, 15 elementi, 1 linguaggio
ItemGroup: Criteria
Physical Activity in Older Patients With Acute Myeloid Leukemia Undergoing Chemotherapy; ODM derived from: https://clinicaltrials.gov/show/NCT00554489

Eligibility Leukemia NCT00544999

- 16-05-18 - 1 modulo, 7 itemgroups, 22 elementi, 1 linguaggio
Itemgroups: Criteria, Inclusion Criteria, Exclusion Criteria, Inclusion Criteria, Exclusion Criteria, Inclusion Criteria, Exclusion Criteria
Everolimus, Cytarabine, and Daunorubicin in Treating Patients With Relapsed Acute Myeloid Leukemia; ODM derived from: https://clinicaltrials.gov/show/NCT00544999

Eligibility Leukemia NCT00576979

- 04-08-17 - 1 modulo, 2 itemgroups, 19 elementi, 1 linguaggio
Itemgroups: Inclusion Criteria, Exclusion Criteria
Intensity-Modulated Radiation Therapy, Etoposide, and Cyclophosphamide Followed By Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia; ODM derived from: https://clinicaltrials.gov/show/NCT00576979

Eligibility Leukemia NCT01378416

- 20-04-17 - 1 modulo, 2 itemgroups, 13 elementi, 1 linguaggio
Itemgroups: Inclusion Criteria, Exclusion Criteria
Pharmacokinetic Trial of Decitabine (Dacogen) Administered as a 3-hour Infusion to Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome; ODM derived from: https://clinicaltrials.gov/show/NCT01378416

Eligibility Leukemia NCT00460421

- 19-04-17 - 1 modulo, 2 itemgroups, 23 elementi, 1 linguaggio
Itemgroups: Inclusion Criteria, Exclusion Criteria
A Phase 1 Dose-escalation Study to Evaluate the Safety and Pharmacokinetics (PK) of Palifermin in Subjects With Acute Leukemias Undergoing HSCT; ODM derived from: https://clinicaltrials.gov/show/NCT00460421

Eligibility Leukemia NCT00454480

- 19-04-17 - 1 modulo, 1 ItemGroup, 17 elementi, 1 linguaggio
ItemGroup: Criteria
Combination Chemotherapy With or Without Gemtuzumab Ozogamicin or Tipifarnib in Treating Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes; ODM derived from: https://clinicaltrials.gov/show/NCT00454480

Eligibility Leukemia NCT00422591

- 19-04-17 - 1 modulo, 2 itemgroups, 10 elementi, 1 linguaggio
Itemgroups: Inclusion Criteria, Exclusion Criteria
Standard Idarubicin and Cytarabine for the Treatment of Acute Myeloid Leukemia (AML); ODM derived from: https://clinicaltrials.gov/show/NCT00422591

Eligibility Leukemia NCT00391560

- 18-04-17 - 1 modulo, 2 itemgroups, 15 elementi, 1 linguaggio
Itemgroups: Inclusion Criteria, Exclusion Criteria
Phase II Study of Perifosine in Patients With Refractory and Relapsed Leukemia; ODM derived from: https://clinicaltrials.gov/show/NCT00391560

Aiuto

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial